Bundibugyo virus disease — the strain at the centre of the 2026 DRC outbreak — is a viral hemorrhagic fever in the Orthoebolavirus genus. Its clinical course tracks the classic Ebola disease pattern with three overlapping phases: an early prodromal phase that looks like severe flu and is easily missed; a progression through gastrointestinal symptoms; and, in a subset of cases, a late hemorrhagic phase. The 2026 DRC cumulative case fatality rate is currently being reported around 25–40% based on cumulative confirmed deaths over confirmed cases, in line with the historical Bundibugyo CFR.
Phase 1 — Prodromal symptoms (days 1–4 after onset)
The prodromal phase of Bundibugyo virus disease typically begins after an incubation period of 2 to 21 days following exposure (median ~8 days). The early symptoms are non-specific and resemble many other tropical febrile illnesses. The most common early symptoms reported across the published Bundibugyo cohorts (Uganda 2007, DRC 2012, DRC 2026) and the current WHO Disease Outbreak News reporting on the DRC 2026 outbreak are:
- Sudden-onset high fever (often ≥ 38.6 °C / 101.5 °F)
- Severe headache and generalised body pain
- Profound weakness and fatigue
- Sore throat
- Loss of appetite
- Conjunctival injection (red eyes)
The clinical challenge is that the prodromal phase of Bundibugyo virus disease overlaps with malaria, typhoid, severe influenza and a number of other endemic febrile illnesses in the DRC and Uganda — and rapid laboratory testing for Bundibugyo virus is not yet widely available outside the INRB Kinshasa reference laboratory. The CDC and WHO operational rule is that any patient presenting with fever and a documented epidemiological link to the affected health zones should be evaluated as a suspected Ebola case until ruled out.
Phase 2 — Gastrointestinal and progression symptoms (days 4–10)
The transition from prodromal to overtly suggestive symptoms usually occurs 3 to 7 days after the first fever. The gastrointestinal phase is what most clinicians describe as the operational tipping point — the moment at which clinical suspicion of Ebola disease tends to overtake the differential of competing tropical febrile illnesses.
- Persistent vomiting and watery diarrhea (sometimes profuse and rapidly dehydrating)
- Abdominal pain
- A measles-like maculopapular rash (typically days 5–7)
- Hiccoughs (a known late-prodromal Ebola sign)
- Difficulty swallowing and continued severe weakness
- Renal dysfunction with reduced urine output
Aggressive supportive care — intravenous fluid resuscitation, electrolyte correction, oxygen support, and management of nutrition — during the GI phase is the single highest-yield intervention in Ebola disease. The published EVD literature consistently shows that patients who reach a treatment centre during this phase and receive structured supportive care have meaningfully better outcomes than those who present late.
Phase 3 — Hemorrhagic symptoms (subset of cases, days 7–14)
Not every Bundibugyo virus disease case progresses to overt hemorrhage; the published Bundibugyo cohorts show frank hemorrhagic features in roughly 30 to 50 percent of severe cases. When present, hemorrhagic symptoms include:
- Bleeding from the gums, nose, or eyes
- Bloody vomit (hematemesis) or bloody diarrhea (melena)
- Petechiae and ecchymoses on the skin
- Bleeding from injection sites or recent venipuncture sites
- Internal bleeding presenting as hypovolaemic shock
The 2026 DRC index case — a nurse who presented in Bunia with fever, vomiting and hemorrhaging on 24 April 2026 — illustrates the rapid clinical trajectory in severe Bundibugyo disease: from prodromal-stage fever to overt hemorrhage within days.
When to seek immediate medical care
For people in or near the affected health zones in Ituri, North Kivu, Kampala or the South Kivu Tshopo-import ring, the operational rule is: same-day medical evaluation for any unexplained fever lasting more than 24 hours, particularly with vomiting, diarrhea, severe headache or fatigue, and with a possible epidemiological link to a confirmed or suspected case, a healthcare facility known to have treated suspected cases, or a funeral / mortuary contact. Tell the clinician explicitly about the exposure history.
For travellers and the global public outside the affected health zones, the practical probability of Ebola disease is very low; WHO and Africa CDC continue to assess the global risk as low. The right rule is still to seek same-day evaluation if febrile illness develops within 21 days of returning from DRC or Uganda, and to declare the travel history explicitly.
What does NOT mean you have Ebola
Equally important: many of the early Ebola symptoms are common features of self-limiting illnesses, and the absence of a clear exposure or travel history meaningfully lowers the prior probability. Headache, sore throat, fatigue, GI upset and rashes in the absence of recent travel to or contact with the affected health zones do not warrant Ebola-specific workup. The CDC US risk assessment remains low; enhanced US entry screening is in place at five international airports for arrivals from DRC and Uganda, but no community-acquired US Ebola case has been reported.